Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Metabolic Regulation of Redox Balance in Cancer.

Purohit V, Simeone DM, Lyssiotis CA.

Cancers (Basel). 2019 Jul 8;11(7). pii: E955. doi: 10.3390/cancers11070955. Review.

2.

ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.

Wang L, Yang H, Zamperone A, Diolaiti D, Palmbos PL, Abel EV, Purohit V, Dolgalev I, Rhim AD, Ljungman M, Hadju CH, Halbrook CJ, Bar-Sagi D, di Magliano MP, Crawford HC, Simeone DM.

Genes Dev. 2019 Jun 1;33(11-12):641-655. doi: 10.1101/gad.323303.118. Epub 2019 May 2.

PMID:
31048544
3.

Insights into gemcitabine resistance and the potential for therapeutic monitoring.

Gebregiworgis T, Bhinderwala F, Purohit V, Chaika NV, Singh PK, Powers R.

Metabolomics. 2018 Nov 27;14(12):156. doi: 10.1007/s11306-018-1452-7.

4.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Sep 11;32(3):392. doi: 10.1016/j.ccell.2017.08.008. No abstract available.

5.

Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells.

Gebregiworgis T, Purohit V, Shukla SK, Tadros S, Chaika NV, Abrego J, Mulder SE, Gunda V, Singh PK, Powers R.

J Proteome Res. 2017 Oct 6;16(10):3536-3546. doi: 10.1021/acs.jproteome.7b00246. Epub 2017 Aug 30.

6.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Jul 10;32(1):71-87.e7. doi: 10.1016/j.ccell.2017.06.004. Erratum in: Cancer Cell. 2017 Sep 11;32(3):392.

7.

Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer.

Goode G, Gunda V, Chaika NV, Purohit V, Yu F, Singh PK.

PLoS One. 2017 Jun 1;12(6):e0179098. doi: 10.1371/journal.pone.0179098. eCollection 2017.

8.

MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer.

Goode G, Gunda V, Chaika NV, Purohit V, Yu F, Singh PK.

PLoS One. 2017 May 2;12(5):e0176820. doi: 10.1371/journal.pone.0176820. eCollection 2017. Erratum in: PLoS One. 2017 Jun 1;12 (6):e0179098.

9.

Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3.

Yang S, Zhang L, Purohit V, Shukla SK, Chen X, Yu F, Fu K, Chen Y, Solheim J, Singh PK, Song W, Dong J.

Oncotarget. 2015 Nov 3;6(34):36019-31. doi: 10.18632/oncotarget.5935.

10.

Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia.

Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, Mehla K, Pipinos II, Powers R, Yu F, Singh PK.

Cancer Metab. 2014 Sep 1;2:18. doi: 10.1186/2049-3002-2-18. eCollection 2014. Erratum in: Cancer Metab. 2014;2:22.

11.

MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer.

Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, Zhang B, Mehla K, Brown RB, Caffrey T, Yu F, Johnson KR, Powers R, Hollingsworth MA, Singh PK.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13787-92. doi: 10.1073/pnas.1203339109. Epub 2012 Aug 6.

12.

Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism.

Torres MP, Rachagani S, Purohit V, Pandey P, Joshi S, Moore ED, Johansson SL, Singh PK, Ganti AK, Batra SK.

Cancer Lett. 2012 Oct 1;323(1):29-40. doi: 10.1016/j.canlet.2012.03.031. Epub 2012 Apr 1.

13.

Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma.

Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, DiMaio D, Anderson JM, Yeh JJ, Johnson KR, Hollingsworth MA, Singh PK.

PLoS One. 2012;7(3):e32996. doi: 10.1371/journal.pone.0032996. Epub 2012 Mar 7.

Supplemental Content

Loading ...
Support Center